Topical cyclosporine-containing formulations and uses thereof
Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
1. An ophthalmic aqueous topical formulation consisting of:
0.087-0.093 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40,
about 0.3 wt % povidone,
about 0.05 wt % sodium chloride,
about 0.20-0.405 wt % sodium phosphate monobasic and about 0.23-0.465 wt % sodium phosphate dibasic, adjusted to a pH of about 5 to about 8 with sodium hydroxide/hydrochloric acid, and
wherein the final volume is made up with water.
2. The ophthalmic topical formulation of claim 1 , wherein the cyclosporine is present in an amount of 0.09 wt % of the formulation.
3. The ophthalmic topical aqueous formulation of claim 1 , wherein the pH of the formulation is about 6.6 to 7.0.
4. A process of preparing the ophthalmic topical formulation of cyclosporine claim 1 , said method comprising the steps of
(1) melting the required amount of polyoxyl lipid,
(2) slowly adding cyclosporine to step (1) and substantially homogenizing the mixture,
(3) adding polyalkoxylated alcohol to step (2) and continue stirring until a uniform homogeneous solution is obtained,
(4) adding buffer system and tonicity agent to the solution obtained from step (3) and continue stirring to achieve a good dissolution,
(5) adding required amount of bioadhesive polymer to the solution of above step,
(6) adjusting the pH of the solution if required, and making up the final volume with water for injection; and
(7) aseptically filtering and filling the solution into unit dose vials.